<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39439719</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2353-9461</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>3</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Biotechnologia</Title><ISOAbbreviation>BioTechnologia (Pozn)</ISOAbbreviation></Journal><ArticleTitle>Induction of an immune response by a nonreplicating adenoviruses-based formulation versus a commercial pseudo-SARS-CoV-2 vaccine.</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>272</EndPage><MedlinePgn>263-272</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5114/bta.2024.141805</ELocationID><Abstract><AbstractText>Screening for effective vaccines requires broad studies on their immunogenicity <i>in vitro</i> and <i>ex vivo</i> . We used a PBMC-based system to assess changes in CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and CD19<sup>+</sup> B cells upon stimulation with different combinations of antigens and adjuvants. We studied the activation mechanism using flow cytometry and two different adenoviral adjuvants characterized by the presence or absence of costimulatory ligands for the ICOS and CD40 receptors. Our studies identified the cellular targets and molecular mechanisms driving ongoing switched-antibody diversification. Class-switched memory B cells were the main precursor cells (95.03% ± 0.38 vs. mock 82.33% ± 0.45, <i>P</i> &lt; 0.05) after treatment with the immunogenic formula: adenovirus armed (MIX1) or not (MIX2) with the ICOS and CD40 ligand, the recombinant receptor binding domain (rRBD), and Lentifect™ SARS-CoV-2 spike-pseudotyped lentivirus (GeneCopoeia, USA). Bcell class-switching towards the IgG<sup>+</sup>IgM<sup>+</sup>- positive phenotypes was noted (~50-fold increase vs. mock, <i>P</i> &lt; 0.05). A significant increase was observed in the CD8<sup>+</sup>T<sub>EM</sub> population of the MIX1 (~2-fold, <i>P</i> &lt; 0.05) and MIX2 (~4.7-fold, <i>P</i> &lt; 0.05) treated samples. CD8<sup>+</sup>T<sub>EMRA</sub> increased when PBMCs were treated with MIX2 (9.63% ± 0.90, <i>P</i> &lt; 0.05) vs. mock (2.63% ± 1.96). Class-switched memory B cells were the dominant antigen-specific cells in primary reactions. We indicated a correlation between the protection offered by vaccine regimens and their ability to induce high frequencies of multifunctional T cells.</AbstractText><CopyrightInformation>© 2024 Institute of Bioorganic Chemistry, Polish Academy of Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baran</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuryk</LastName><ForeName>Łukasz</ForeName><Initials>Ł</Initials><AffiliationInfo><Affiliation>National Institute of Public Health National Institute of Hygiene (NIH) - National Institute of Research, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garofalo</LastName><ForeName>Mariangela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pancer</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Institute of Public Health National Institute of Hygiene (NIH) - National Institute of Research, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieczorek</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute of Public Health National Institute of Hygiene (NIH) - National Institute of Research, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazek</LastName><ForeName>Michalina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staniszewska</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warszawa, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>BioTechnologia (Pozn)</MedlineTA><NlmUniqueID>9702407</NlmUniqueID><ISSNLinking>0860-7796</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adenoviruses</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39439719</ArticleId><ArticleId IdType="pmc">PMC11492889</ArticleId><ArticleId IdType="doi">10.5114/bta.2024.141805</ArticleId><ArticleId IdType="pii">BTA-105-3-54526</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baran J., Kuryk L., Szczepińska T., Lazniewski M., Garofalo M., Mazurkiewicz A., et al. . (2023) In vitro immune evaluation of adenoviral vector-based platform for infectious diseases. BioTechnologia 104: 403–419. 10.5114/bta.2023.132775</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/bta.2023.132775</ArticleId><ArticleId IdType="pmc">PMC10777723</ArticleId><ArticleId IdType="pubmed">38213479</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J., Loyal L., Frentsch M., Wendisch D., Georg P., Kurth F., et al. . (2020) SARS-CoV-2-reactive T-cells in healthy donors and patients with COVID-19. Nature 587: 270–274. 10.1038/s41586-020-2598-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2598-9</ArticleId><ArticleId IdType="pubmed">32726801</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft M. (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3: 609–620. 10.1038/nri1148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1148</ArticleId><ArticleId IdType="pubmed">12974476</ArticleId></ArticleIdList></Reference><Reference><Citation>Excler J.-L., Saville M., Berkley S., Kim J.H. (2021) Vaccine development for emerging infectious diseases. Nat. Med. 27: 591–600. 10.1038/s41591-021-01301-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01301-0</ArticleId><ArticleId IdType="pubmed">33846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo M., Bertinato L., Staniszewska M., Wieczorek M., Salmaso S., Schrom S., et al. . (2021a) Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics 13: 547. 10.3390/pharmaceutics13040547</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13040547</ArticleId><ArticleId IdType="pmc">PMC8070801</ArticleId><ArticleId IdType="pubmed">33919827</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo M., Bertinato L., Staniszewska M., Wieczorek M., Salmaso S., Schrom S., et al. . (2021b) Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics 13(4): 547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8070801</ArticleId><ArticleId IdType="pubmed">33919827</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo M., Staniszewska M., Salmaso S., Caliceti P., Pancer K.W., Wieczorek M., Kuryk L. (2020) Prospects of replication-deficient adenovirus based vaccine development against SARS-CoV-2. Vaccines 8: 293. 10.3390/vaccines8020293</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020293</ArticleId><ArticleId IdType="pmc">PMC7349996</ArticleId><ArticleId IdType="pubmed">32531955</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., et al. . (2020) Targets of T-cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181: 1489–1501. 10.1016/j.cell.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiveland C.R. (2015) Peripheral blood mononuclear cells. [in:] The impact of food bioactives on health. Verhoeckx K., Cotter P., López-Expósito I., Kleiveland C., Lea T., Mackie A., Requena T., Swiatecka D., Wichers H. (Eds.) Springer International Publishing, Cham: 161–167. 10.1007/978-3-319-16104-4_15</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-16104-4_15</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlin R., Godot V., Cardinaud S., Galhaut M., Coleon S., Zurawski S., et al. . (2021) Targeting the SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection against infection in convalescent macaques. Nat. Commun. 12: 5215. 10.1038/s41467-021-25382-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25382-0</ArticleId><ArticleId IdType="pmc">PMC8410935</ArticleId><ArticleId IdType="pubmed">34471122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J., Grifoni A., Tarke A., Sidney J., Ramirez S.I., Dan J.M., et al. . (2020) Selective and cross-reactive SARS-CoV-2 T-cell epitopes in unexposed humans. Science 370: 89–94. 10.1126/science.abd3871</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3871</ArticleId><ArticleId IdType="pmc">PMC7574914</ArticleId><ArticleId IdType="pubmed">32753554</ArticleId></ArticleIdList></Reference><Reference><Citation>McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L. (2011) Molecular programming of B-cell memory. Nat. Rev. Immunol. 12: 24–34. 10.1038/nri3128</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3128</ArticleId><ArticleId IdType="pmc">PMC3947622</ArticleId><ArticleId IdType="pubmed">22158414</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff B.J., Ramírez-Suástegui C., Fajardo V., Chee S.J., Kusnadi A., Simon H., et al. . (2020) Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T-cells. 10.2139/ssrn.3641939 (preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3641939</ArticleId><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Melgaço J.G., Brito e Cunha D., Azamor T., da Silva A.M.V., Tubarăo L.N., Gonçalves R.B., et al. . (2020) Cellular and molecular immunology approaches for the development of immunotherapies against the new coronavirus (SARS-CoV-2): challenges to near-future breakthroughs. J. Immunol. Res. 2020: e8827670. 10.1155/2020/8827670</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8827670</ArticleId><ArticleId IdType="pmc">PMC7753942</ArticleId><ArticleId IdType="pubmed">33426096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogando N.S., Dalebout T.J., Zevenhoven-Dobbe J.C., Limpens R.W.A.L., van der Meer Y., Caly L., et al. . (2020) SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. General Virol. 101: 925–940. 10.1099/jgv.0.001453</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001453</ArticleId><ArticleId IdType="pmc">PMC7654748</ArticleId><ArticleId IdType="pubmed">32568027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranki T., Joensuu T., Jäger E., Karbach J., Wahle C., Kairemo K., et al. . (2014) Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization. OncoImmunology 3: e958937. 10.4161/21624011.2014.958937</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21624011.2014.958937</ArticleId><ArticleId IdType="pmc">PMC4292415</ArticleId><ArticleId IdType="pubmed">25941579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranki T., Pesonen S., Hemminki A., Partanen K., Kairemo K., Alanko T., et al. . (2016) Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers. J. Immunother. Cancer 4: 17. 10.1186/s40425-016-0121-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-016-0121-5</ArticleId><ArticleId IdType="pmc">PMC4791966</ArticleId><ArticleId IdType="pubmed">26981247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sałkowska A., Karwaciak I., Karaś K., Dastych J., Ratajewski M. (2020) SARS-CoV-2 Proteins induce IFNG in Th1 lymphocytes generated from CD4+ cells from healthy, unexposed polish donors. Vaccines (Basel) 8: 673. 10.3390/vaccines8040673</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040673</ArticleId><ArticleId IdType="pmc">PMC7712722</ArticleId><ArticleId IdType="pubmed">33198287</ArticleId></ArticleIdList></Reference><Reference><Citation>Seder R.A., Darrah P.A., Roederer M. (2008) T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247–258. 10.1038/nri2274</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2274</ArticleId><ArticleId IdType="pubmed">18323851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Rudra D. (2018) Emerging functions of regulatory T-cells in tissue homeostasis. Front. Immunol. 9: 883. 10.3389/fimmu.2018.00883</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00883</ArticleId><ArticleId IdType="pmc">PMC5989423</ArticleId><ArticleId IdType="pubmed">29887862</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamming L.A., Duque D., Tran A., Zhang W., Pfeifle A., Laryea E., et al. . (2022) DNA based vaccine expressing SARS-CoV-2 spike-CD40L fusion protein confers protection against challenge in a Syrian mamster model. Front. Immunol. 12: 785349. 10.3389/fimmu.2021.785349</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.785349</ArticleId><ArticleId IdType="pmc">PMC8789660</ArticleId><ArticleId IdType="pubmed">35095861</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Calle G., Born P.A., Koutsoumpli G., Gonzalez-Rodriguez M.I., Hinrichs W.L.J., Huckriede A.L.W. (2019) A PBMC-based system to assess human T Cell responses to influenza vaccine candidates in vitro. Vaccines 7: 181. 10.3390/vaccines7040181</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7040181</ArticleId><ArticleId IdType="pmc">PMC6963913</ArticleId><ArticleId IdType="pubmed">31766202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassilev L., Ranki T., Joensuu T., Jäger E., Karbach J., Wahle C., et al. . (2015) Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. OncoImmunology 4: e1017702. 10.1080/2162402X.2015.1017702</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1017702</ArticleId><ArticleId IdType="pmc">PMC4485730</ArticleId><ArticleId IdType="pubmed">26140248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-P., Wang Z.-G., Liu S.-L. (2021) Current status and future trends of vaccine development against viral infection and disease. New J. Chem. 45: 7437–7449. 10.1039/D1NJ00996F</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1NJ00996F</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhao Y., Bollas A., Wang Y., Au K.F. (2021) Nanopore sequencing technology, bioinformatics and applications. Nat. Biotechnol. 39: 1348–1365. 10.1038/s41587-021-01108-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01108-x</ArticleId><ArticleId IdType="pmc">PMC8988251</ArticleId><ArticleId IdType="pubmed">34750572</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Schmitz K.S., Raadsen M.P., Grifoni A., Okba N.M.A., Endeman H.,et al. . (2020) Phenotype and kinetics of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5: eabd2071. 10.1126/sciimmunol.abd2071</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd2071</ArticleId><ArticleId IdType="pmc">PMC7319493</ArticleId><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M. (2004) SARS immunity and vaccination. Cell Mol. Immunol. 1: 193–198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219167</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>